The Harvard Drug Group LLC dba Major

Form 483 issued March 20, 2026 · La Vergne, Tennessee

Inspection
Mar 16 – Mar 20, 2026
Observations
1
Pages
4
FEI number
1818658

In short: On March 20, 2026, FDA issued a Form 483 with 1 observation to The Harvard Drug Group LLC dba Major in La Vergne, Tennessee (FEI 1818658) after an inspection that ran Mar 16 – Mar 20, 2026. The investigators were Demario L. Walls, Nelson N. Ayangho and Sarah E. Venti. Most observations concern quality system; the most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit).

At a glance

1 of 1 observations on this 483 concern quality system.

Quality system1

Most cited: 21 CFR 211.22(d) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    The responsibilities and procedures applicable to the quality control unit…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at The Harvard Drug Group LLC dba Major?

FDA listed 1 observation on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit). The opening words of each observation are shown on this page.

Who inspected The Harvard Drug Group LLC dba Major?

Demario L. Walls, Nelson N. Ayangho and Sarah E. Venti are named on this Form 483, for the inspection of Mar 16 – Mar 20, 2026. Each investigator has a profile showing what they cite most.

When was The Harvard Drug Group LLC dba Major inspected by FDA?

The inspection ran Mar 16 – Mar 20, 2026, and the Form 483 is dated March 20, 2026.

How do I get the full Form 483 for The Harvard Drug Group LLC dba Major?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free